Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges

As U.S. markets navigate the complexities of earnings reports and interest rate expectations, investors are increasingly exploring diverse opportunities beyond established giants like Tesla and Apple. Penny stocks, though sometimes considered a relic of past market trends, continue to attract attention due to their potential for growth at lower price points. By focusing on companies with strong financials and solid fundamentals, investors can uncover promising prospects within this often-overlooked segment of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$91.49M	★★★★★★
BAB (OTCPK:BABB)	$0.884275	$6.54M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.50	$10.2M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.65	$2B	★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.285	$11.23M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.68	$48.23M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.13	$20.22M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.908	$82.23M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.41	$380.13M	★★★★☆☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Anixa Biosciences (NasdaqCM:ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of approximately $73.40 million.

Operations: Anixa Biosciences, Inc. currently does not report any revenue segments.

Market Cap: $73.4M

Anixa Biosciences, Inc. is a pre-revenue biotechnology company with a market cap of approximately US$73.40 million, focusing on oncology therapies and vaccines. Despite being unprofitable with increasing losses over the past five years, it remains debt-free and has sufficient cash runway for over a year based on its current free cash flow. Recent developments include dosing in Phase 1 trials for CAR-T therapy targeting ovarian cancer and positive data from its breast cancer vaccine trial in collaboration with Cleveland Clinic. The company's management and board are experienced, though profitability is not expected within the next three years.

• Jump into the full analysis health report here for a deeper understanding of Anixa Biosciences.
• Gain insights into Anixa Biosciences' future direction by reviewing our growth report.

One Stop Systems (NasdaqCM:OSS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: One Stop Systems, Inc. designs, manufactures, and markets high-performance computing and storage hardware and software for edge deployments globally, with a market cap of $69.47 million.

Operations: The company's revenue is derived from two segments: Bressner, contributing $28.79 million, and One Stop Systems, Inc. (including Concept Development Inc.), accounting for $23.92 million.

Market Cap: $69.47M

One Stop Systems, Inc., with a market cap of US$69.47 million, operates in the high-performance computing sector but remains unprofitable with increasing losses over the past five years. Despite this, the company maintains a strong cash position exceeding its debt and has a sufficient runway for over three years due to positive free cash flow. Recent developments include securing orders from defense and AI infrastructure clients, potentially boosting future revenue streams. However, management changes may affect strategic continuity as they navigate volatile market conditions and aim for revenue growth projected at 9.47% annually.

• Get an in-depth perspective on One Stop Systems' performance by reading our balance sheet health report here.
• Assess One Stop Systems' future earnings estimates with our detailed growth reports.

Granite Point Mortgage Trust (NYSE:GPMT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Granite Point Mortgage Trust Inc. is a real estate investment trust that focuses on originating, investing in, and managing senior floating-rate commercial mortgage loans and other debt-related commercial real estate investments in the United States, with a market cap of $141.38 million.

Operations: Granite Point Mortgage Trust's revenue segment is derived from its operations in the REIT - Mortgage sector, with a reported revenue of -$140.09 million.

Market Cap: $141.38M

Granite Point Mortgage Trust, with a market cap of US$141.38 million, is currently unprofitable and pre-revenue, reporting a significant net loss of US$168.22 million for the first nine months of 2024. Despite this, its short-term assets significantly exceed both short- and long-term liabilities, providing financial stability. The company has a cash runway exceeding three years due to positive free cash flow but faces challenges with high debt levels and negative return on equity. Recent board appointments bring seasoned real estate investment expertise that may guide strategic adjustments amidst ongoing financial difficulties.

• Click here and access our complete financial health analysis report to understand the dynamics of Granite Point Mortgage Trust.
• Learn about Granite Point Mortgage Trust's future growth trajectory here.

Key Takeaways

• Access the full spectrum of 713 US Penny Stocks by clicking on this link.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com